Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.
|アブストラクト||Following a severe case of rhabdomyolysis in our University Hospital after a co-administration of atorvastatin and fusidic acid, we describe this interaction as this combination is not clearly contraindicated in some countries, particularly for long-term treatment by fusidic acid. All cases of rhabdomyolysis during a co-administration of a statin and fusidic acid were identified in the literature and in the World and Health Organization database, VigiBase(R). In the literature, 29 cases of rhabdomyolysis were identified; mean age was 66 years, median duration of co-administration before rhabdomyolysis occurrence was 21 days, 28% of cases were fatal. In VigiBase(R), 182 cases were retrieved; mean age was 68 years, median duration of co-administration before rhabdomyolysis was 31 days and 24% of cases were fatal. Owing to the high fatality associated with this co-administration and the long duration of treatment before rhabdomyolysis occurrence, fusidic acid should be used if there is no appropriate alternative, as long as statin therapy is interrupted for the duration of fusidic acid therapy, and perhaps a week longer. Rarely will interruption of this sort have adverse consequences for the patient.|
|ジャーナル名||British journal of clinical pharmacology|
|投稿者||Deljehier, T; Pariente, A; Miremont-Salame, G; Haramburu, F; Nguyen, L; Rubin, S; Rigothier, C; Theophile, H|
|組織名||Regional Pharmacovigilance Centre, Department of Medical Pharmacology, CHU;Bordeaux, F-33000, Bordeaux, France.;Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team;Pharmacoepidemiology, UMR 1219, F-33000, Bordeaux, France.;Univ. Bordeaux, France.;Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux,;Bordeaux, France.;INSERM, BioTis, UMR 1026, Univ. Bordeaux (France).|